Skip to main content

Refractory Angina

3
Pipeline Programs
4
Companies
6
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Shockwave Medical
Shockwave MedicalCA - Santa Clara
3 programs
1
Neovasc ReducerPhase 21 trial
Arm 1: treatment with Shockwave ReducerN/A1 trial
Neovac coronary sinus reducerN/A1 trial
Active Trials
NCT05102019Recruiting380Est. Jan 2032
NCT01566175Recruiting100Est. Dec 2031
NCT01205893Completed104Est. Nov 2013
Imbria Pharmaceuticals
1 program
1
IMB-1018972Phase 21 trial
Active Trials
NCT04306237Withdrawn0Est. Apr 2025
XyloCor Therapeutics
XyloCor TherapeuticsPA - King of Prussia
1 program
1
XC001Phase 21 trial
Active Trials
NCT07048808Recruiting106Est. Jun 2027
BioCardia
BioCardiaCA - Sunnyvale
1 program
CardiAMP Cell Therapy SystemN/A1 trial
Active Trials
NCT03455725Active Not Recruiting343Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
XyloCor TherapeuticsXC001
Imbria PharmaceuticalsIMB-1018972
Shockwave MedicalNeovasc Reducer
Shockwave MedicalArm 1: treatment with Shockwave Reducer
BioCardiaCardiAMP Cell Therapy System
Shockwave MedicalNeovac coronary sinus reducer

Clinical Trials (6)

Total enrollment: 1,033 patients across 6 trials

NCT07048808XyloCor TherapeuticsXC001

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

Start: Jun 2025Est. completion: Jun 2027106 patients
Phase 2Recruiting
NCT04306237Imbria PharmaceuticalsIMB-1018972

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

Start: May 2020Est. completion: Apr 20250
Phase 2Withdrawn
NCT01205893Shockwave MedicalNeovasc Reducer

Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA

Start: Sep 2010Est. completion: Nov 2013104 patients
Phase 2Completed
NCT05102019Shockwave MedicalArm 1: treatment with Shockwave Reducer

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Start: Jan 2022Est. completion: Jan 2032380 patients
N/ARecruiting
NCT03455725BioCardiaCardiAMP Cell Therapy System

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Start: Jun 2021Est. completion: Dec 2027343 patients
N/AActive Not Recruiting
NCT01566175Shockwave MedicalNeovac coronary sinus reducer

Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization

Start: Aug 2011Est. completion: Dec 2031100 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,033 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.